• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

“Lung-RADS” lung cancer screening may reduce false positives vs NLST screening

byKenan Celtik, MSandSai Folmsbee
February 10, 2015
in Chronic Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. When applied to the original NLST cohort, Lung-RADS lung cancer screening criteria had a lower false positive rate, a higher positive predictive value and a lower sensitivity, compared to the NLST criteria. 

Evidence Rating Level: 2 (Good)

Study Rundown: The National Lung Screening Trial (NLST) criteria for lung cancer screening resulted in a 20% reduction in lung cancer-specific death, but also had a high rate of false positives. To reduce these, the American College of Radiology (ACR) developed the Lung Imaging Reporting and Data System (Lung-RADS), and this retrospective analysis sought to investigate how this screening criteria for lung nodules could impact the performance characteristics (sensitivity, false positive rate, positive predictive value) when applied to the original NLST cohort of high-risk current and former smokers. Notably, the positivity criterion for Lung-RADS was 6mm diameter for a solid nodule, compared to 4mm with NLST. Compared to NLST, the Lung-RADS had a significantly lower sensitivity, lower false-positive rate, and higher positive predictive value in both baseline and after-baseline screenings. Lung-RADS would have avoided half of the baseline screening false positives, three-fourths of the after-baseline false-positives and subsequently sending a large number of baseline false positive cases for invasive diagnostic testing. However, Lung-RADS also would have missed 86 cancers. These true positives had similar stages of cancers as those correctly identified by Lung-RADS. Importantly, there was no significant difference in lung cancer-specific survival between cancers that were missed and not missed by Lung-RADS. The major limitations to this study were its retrospective nature and the possibility of confirmation bias amongst radiologists.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Performance of ACR Lung-RADS in a Clinical CT Lung Screening Program

In-Depth [retrospective cohort]: In this study, the ACR Lung-RADS lung nodule screening criteria were applied retrospectively to the NLST cohort of 26,455 high-risk current and former smokers between 55 to 74 years old with >30 pack-years history. For baseline screenings, Lung-RADS showed an 8.6% reduction in sensitivity (p <0.001; NLST 93.5% to Lung-RADS 84.9%) and reduced the false-positive rate by 13.8% (p<0.001; NLST 26.6% to Lung-RADS 12.8%). The positive predictive value at baseline was significantly higher with Lung-RADS compared to NLST (p <0.001). After-baseline screening, sensitivity was decreased by 15.2% using Lung-RADS (p <0.001; NLST 93.8% to Lung-RADS 78.6%). The after-baseline false positive rate was 16.5% lower (p <0.001) using Lung-RADS (5.3%; NLST 21.8%), and the corresponding positive predictive value was significantly higher with Lung-RADS (p <0.001). NPV was very high (≥99.8%) for both Lung-RADS and NLST at all screenings, though it was still significantly higher for NLST than Lung-RADS.

Image: PD

RELATED REPORTS

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: lung cancer
Previous Post

The V-HeFT I: Hydralazine and isosorbide dinitrate in heart failure [Classics Series]

Next Post

Strict blood pressure control in diabetics associated with fewer complications

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

July 1, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

June 14, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Next Post
Updated USPSTF guidelines favor treatment of mild gestational diabetes

Strict blood pressure control in diabetics associated with fewer complications

Levodopa for Parkinson’s disease more effective than newer generation therapies

Creatine not shown to slow progression of Parkinson disease

Oral iron supplementation reduces hemoglobin time to recovery in blood donors

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Type of compensation model influences gender pay gap in primary care
  • MRI effective for the assessment of acute appendicitis in pregnancy [Classics Series]
  • Racial differences exist in emphysema prevalence in adults with normal spirometry findings
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.